Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Soligenix, Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases and public health preparedness indications where there are limited or no approved treatment options. The company operates across the biotechnology and pharmaceutical industries, with an emphasis on orphan and neglected indications that may qualify for regulatory incentives such as orphan drug status, priority review vouchers, and government-supported development pathways.
Soligenix’s primary revenue drivers are its proprietary clinical-stage drug candidates and vaccine programs, which are organized around immunology-based therapeutics and thermostabilized vaccines. Its strategic positioning centers on targeting well-defined patient populations, leveraging non-dilutive funding, and advancing assets with clear regulatory pathways. The company traces its origins to 1987 and evolved through multiple strategic transformations, including a name change from DOR BioPharma in 2014, to focus more narrowly on rare diseases and biodefense-oriented vaccines.
Business Operations
Soligenix conducts its operations through two primary business segments: Specialized Biotherapeutics and Public Health Solutions. The Specialized Biotherapeutics segment focuses on developing treatments for rare and orphan diseases, with its most advanced program being HyBryte™ (SGX301), a photodynamic therapy for cutaneous T-cell lymphoma (CTCL). This segment also includes immunomodulatory therapeutic candidates such as dusquetide (SGX942), although development status and partnering activity for this asset vary by indication and period.
The Public Health Solutions segment is dedicated to vaccines and therapeutics addressing biodefense and emerging infectious disease threats. This business line leverages the company’s proprietary ThermoVax® platform, designed to produce heat-stable vaccines suitable for stockpiling. Programs under this segment have included vaccine candidates targeting ricin toxin exposure and other government-prioritized threats. Operations are primarily U.S.-based, and revenue generation to date has largely depended on government contracts, grants, and research funding rather than commercial product sales. The company operates through subsidiaries including Soligenix Therapeutics, Inc. and Soligenix Vaccines, Inc.
Strategic Position & Investments
Soligenix’s strategic direction emphasizes advancing late-stage rare disease assets toward potential regulatory approval while continuing to pursue non-dilutive funding opportunities for its public health programs. A key growth initiative has been the continued clinical development of HyBryte™, which has received orphan drug designation in the U.S. and Europe for CTCL, positioning it as a potential first-in-class or differentiated therapy if approved.
The company has historically relied on a combination of equity financing and government-sponsored funding rather than large-scale acquisitions. Its investment focus remains internal, prioritizing platform technologies such as ThermoVax® and selectively advancing pipeline candidates with defined regulatory and commercial pathways. Public disclosures indicate limited acquisition activity, and data on additional material investments or joint ventures beyond government-supported collaborations is inconclusive based on available public sources.
Geographic Footprint
Soligenix is headquartered in Princeton, New Jersey, and its operations are primarily concentrated in the United States. The company conducts clinical development, regulatory activities, and corporate management domestically, with clinical trial sites occasionally extending into Europe depending on study design and regulatory requirements.
While Soligenix does not maintain large-scale international commercial operations, its vaccine and biodefense programs are designed to address global public health threats. Its intellectual property portfolio and regulatory strategy reflect potential applicability across North America and Europe, particularly in regions that participate in coordinated biodefense and pandemic preparedness initiatives.
Leadership & Governance
Soligenix is led by an executive team with experience in biopharmaceutical development, regulatory strategy, and capital markets, with a governance structure overseen by a board of directors. The company’s leadership philosophy emphasizes capital efficiency, targeted clinical development, and leveraging regulatory incentives to advance niche therapies.
Key executives include:
- Christopher J. Schaber, PhD – President and Chief Executive Officer
- Jonathan Guarino – Chief Financial Officer
- Ellen M. Phiddian, PhD – Vice President, Regulatory Affairs
- Sean A. Sullivan – Vice President, Business Development
Dr. Schaber, who has led the company for multiple years, has been central to shaping Soligenix’s strategic focus on rare diseases and public health solutions, guiding its evolution from a broader biopharma model to a more specialized, incentive-driven development strategy.